Hyperspectral Imaging to Assess and Predict Diabetic Foot Ulcers

This study has been completed.
Sponsor:
Collaborators:
The Cleveland Clinic
Olive View-UCLA Medical Center
University of Pennsylvania
Information provided by:
HyperMed, Inc
ClinicalTrials.gov Identifier:
NCT00617916
First received: February 6, 2008
Last updated: June 2, 2009
Last verified: June 2009
  Purpose

This study is designed to test a prototype imaging instrument that relies on Medical HyperSpectral Imaging (MHSI) technology for the assessment and prediction of diabetic foot ulceration and wound healing. The imaging system utilizes the biomarkers of oxyhemoglobin (oxyHb) and deoxyhemoglobin (deoxyHb), in the upper layers of skin on the foot as: a metric for assessing wound healing, a reflection of microvascular disease, and determining tissue at risk for forming new ulcers. MHSI results will also be compare with ABI and TcPO2 measurements.


Condition
Diabetic Foot Ulcers

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Hyperspectral Imaging to Assess and Predict Diabetic Foot Ulcers

Resource links provided by NLM:


Further study details as provided by HyperMed, Inc:

Enrollment: 256
Study Start Date: March 2006
Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Detailed Description:

ULCER HEALING STUDY: This is a study comparing measurements from a cohort of 66 diabetic subjects (30 Type 1 and 36 Type 2) with at least one foot ulcer. The study will take place at three medical centers. Each center will enroll 22 subjects (10 Type 1 and 12 Type 2). Subjects will be required to participate in eleven (11) clinic visits over a 6 month period. The first visit will last approximately three hours and each of the other visits will last about two hours. The eleven visits will be scheduled as follows in the Table to the right.

At the initial visit the subject will give informed consent and a full medical history, and will schedule the dates of the remaining visits for the study. The subject recruiter will contact each subject one week prior to each subsequent visit to either confirm the subject's attendance or to re-schedule the visit.

NEW ULCER PREDICTION STUDY: This is a study comparing measurements of 210 "high risk" diabetic subjects (90 Type 1 and 120 Type 2) over an 18-24 month period. The study will take place at three medical centers. Each center will enroll 70 subjects (30 Type 1 and 40 Type 2). Subjects will all be required to participate in nine (9) clinic visits. The nine visits will be scheduled as follows in the Table to the right.

The first visit will last approximately three hours and each of the other visits will last about 2 hours. At the initial visit the subject will give informed consent and a full medical history, and will schedule the dates of the visits for the rest of the study. The subject recruiter will contact each subject one week prior to each subsequent visit to either confirm the subject's attendance or to re-schedule the visit.

  Eligibility

Ages Eligible for Study:   21 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Clinic population - diabetic patients at high risk for ulceration

Criteria

Ulcer Healing Study

Inclusion Criteria:

  • Subjects with Type 1 diabetes (defined as diabetes beginning before age 35, requiring insulin, and diagnosed with diabetes for more than six months) or Type 2 diabetes.
  • Presence of at least one foot ulcer

Exclusion criteria:

  • Peripheral arterial occlusive disease (PAD) that is severe enough to require surgical bypass operation.
  • Cardiovascular disease as demonstrated in only these instances: congestive heart failure that leads to severe edema at the lower extremity, stroke or transient ischemic attack with residual nerve dysfunction.
  • Uncontrolled hypertension: SBP>190 mmHg or DBP > 110 mmHg
  • End stage renal disease (subjects on renal dialysis or kidney transplantation)
  • Any other serious chronic disease that can affect wound healing
  • Subjects currently on any of the following medications: Glucocorticoids, Antineoplastics
  • Females if lactating or pregnant or, if of childbearing potential, unwilling to use standard birth control. All females of childbearing potential will undergo a pregnancy test during each visit.

NEW ULCER PREDICTION STUDY:

Inclusion criteria:

  • Subjects with Type 1 diabetes (defined as diabetes beginning before age 35, requiring insulin, and diagnosed with diabetes for more than six months) or Type 2 diabetes.
  • Subject without foot ulcers but at "high risk" for foot ulceration. In order to define "high risk" for this study, we are using the International Working Group standards:

    1. Advanced neuropathy, defined by loss of protective sensation in the foot with a vibrational perception threshold (VPT) over 25mHz or inability to detect Semmes Weinstein 5.07 (10g) monofilament
    2. Presence of significant deformity
    3. Peripheral vascular disease with ankle brachial index < 0.7
    4. History of previous ulceration or presence of a foot ulcer
    5. At least one foot that is ulcer free at the time of enrollment

Exclusion criteria:

  • Peripheral arterial occlusive disease (PAD) that is severe enough to require surgical bypass operation.
  • Cardiovascular disease as demonstrated in only these instances: congestive heart failure that leads to severe edema at the lower extremity, stroke or transient ischemic attack with residual nerve dysfunction.
  • Uncontrolled hypertension: SBP > 190 mmHg or DBP > 110 mmHg
  • End stage renal disease (subjects on renal dialysis or kidney transplantation)
  • Any other serious chronic disease that can affect wound healing
  • Subjects on any of the following medications: Glucocorticoids and Antineoplastic agents
  • Females if lactating or pregnant or, if of childbearing potential, unwilling to use standard birth control. All females of childbearing potential will undergo a pregnancy test during each visit.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00617916

Locations
United States, California
Olive View UCLA Medical Center
Sylmar, California, United States, 91342
United States, Ohio
Lerner Research Institute, The Cleveland Clinic
Cleveland, Ohio, United States, 44195
United States, Pennsylvania
University of Pennslyvania Healthcare System
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
HyperMed, Inc
The Cleveland Clinic
Olive View-UCLA Medical Center
University of Pennsylvania
Investigators
Principal Investigator: Brian L Davis, PhD The Cleveland Clinic
Principal Investigator: Aksone Nouvong, DPM Olive View-UCLA Medical Center
Principal Investigator: Emile Mohler, MD University of Pennsylvania
  More Information

Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Kevin Schomacker, PhD, HyperMed, Inc.
ClinicalTrials.gov Identifier: NCT00617916     History of Changes
Other Study ID Numbers: 2005-001, R42-DK069871
Study First Received: February 6, 2008
Last Updated: June 2, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by HyperMed, Inc:
hyperspectral imaging
tissue oxygenation
diabetic foot ulcers
wound healing
prevention

Additional relevant MeSH terms:
Diabetic Foot
Ulcer
Foot Ulcer
Pathologic Processes
Foot Diseases
Skin Diseases
Leg Ulcer
Skin Ulcer
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies

ClinicalTrials.gov processed this record on April 17, 2014